Trial Profile

A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 02 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms KEYLYNK008; MK-7339-008KEYLYNK-008
Sponsors Merck Sharp & Dohme Corp.

16 Jan 2025 Planned End Date changed from 12 Mar 2025 to 31 Dec 2025.
06 Nov 2024 The protocol has been amended to change in the study time frame for its both primary endpoints.
10 Apr 2024 Results assessing effect of addition of ola to pembro as maintenance therapy after 1L pembro + chemo for metastatic sqNSCLC presented at the 115th Annual Meeting of the American Association for Cancer Research.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com